Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes.
Hui XuMaosheng LinYingying HuLi ZhangQiaoqiao LiJinhan ZhuShi WangMian XiPublished in: The oncologist (2020)
The purpose of this study was to investigate the relationship between clinical characteristics, as well as dosimetric parameters, and the risk of treatment-related lymphopenia in 436 patients with esophageal squamous cell carcinoma who received definitive chemoradiotherapy. Grade 4 (G4) lymphopenia was observed in 23.6% of patients during radiotherapy. G4 lymphopenia was associated with larger planning target volumes, higher lung V10 and heart V10 , and worse survival. Then, a nomogram was built based on multivariate analysis, yielding excellent performance to predict overall survival. Prospective studies are needed to investigate potential approaches for mitigating severe lymphopenia, which may ultimately convert into survival benefits.
Keyphrases
- locally advanced
- radiation therapy
- rectal cancer
- end stage renal disease
- free survival
- squamous cell carcinoma
- ejection fraction
- early stage
- newly diagnosed
- chronic kidney disease
- heart failure
- prognostic factors
- atrial fibrillation
- risk assessment
- radiation induced
- patient reported outcomes
- climate change
- replacement therapy
- patient reported